

1 Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk  
2 Persons

3

4 Nischal Ranganath, MD, PhD<sup>1</sup>; John C. O'Horo, MD, MPH<sup>1,2</sup>; Douglas W. Challener, MD, MS<sup>1</sup>; Sidna M.  
5 Tullidge-Scheitel, MD, MPH<sup>3</sup>; Marsha L. Pike, APRN, CNS, DNP<sup>4</sup>; Michael O'Brien, R. Ph<sup>5</sup>; Raymund R.  
6 Razonable, MD<sup>1</sup>; Aditya Shah, MBBS<sup>1</sup>

7

8 1. Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic,  
9 Rochester, MN USA

10 2. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA

11 3. Division of Community Internal Medicine, Mayo Clinic, Rochester, MN, USA

12 4. Department of Nursing, Mayo Clinic, Rochester, MN, USA

13 5. Department of Pharmacy, Mayo Clinic, Rochester, MN, USA

14

15 **Corresponding Author:**

16 Aditya Shah MBBS

17 Mayo Clinic Division of Public Health, Infectious Diseases, and Occupational Medicine

18 200 1<sup>st</sup> St. SW, Rochester, MN 55905

19 Email: [shah.aditya@mayo.edu](mailto:shah.aditya@mayo.edu)

20

1 **ABSTRACT**

2 In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for coronavirus disease-2019,  
3 two patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of  
4 symptoms, which were generally mild, at median of 9 days after treatment, and all resolved without  
5 additional COVID-19-directed therapy.

6  
7

ACCEPTED MANUSCRIPT

## 1 INTRODUCTION

2 Nirmatrelvir, the main protease inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-  
3 CoV-2), co-formulated with ritonavir as its pharmacokinetic booster, is authorized for treatment of mild  
4 to moderate coronavirus disease-2019 (COVID-19) in high-risk individuals [1]. This emergency use  
5 authorization (EUA) is supported by the EPIC-HR randomized controlled trial that demonstrated an 89%  
6 relative risk reduction of hospitalization and death among unvaccinated patients who received  
7 treatment [2]. With widespread use since January 2022, recurrence of symptoms in some patients after  
8 completion of nirmatrelvir-ritonavir (NM/R) treatment have been increasingly reported [3]. We aimed  
9 to gain insight into this rebound phenomenon by assessing the incidence, clinical course, and outcomes  
10 of patients treated with NM/R in our program.

## 11 METHODS

12 After Institutional Review Board (IRB# 22-004922) approval, we performed a retrospective review of  
13 patients at Mayo Clinic in Rochester who received NM/R for mild-to-moderate SARS-CoV-2 infection. At  
14 our center, outpatient therapies were coordinated by the Monoclonal Antibody Treatment Program and  
15 the Midwest COVID-19 Care Team, a centralized multidisciplinary team that assesses patients for  
16 eligibility for treatment according to the FDA EUA criteria [4]. Each patient is assigned a Monoclonal  
17 Antibody Screening Score (MASS) and COVID Antibody Screening Tool Score (CAST) that categorizes a  
18 person's risk for severe disease progression, to facilitate appropriate allocation of NM/R therapy [5]. If  
19 eligible, patients were given the option for oral NM/R, intravenous remdesivir, or intravenous  
20 monoclonal antibody (sotrovimab, bebtelovimab). The final decision on drug treatment is based on  
21 shared decision making between patients and providers. Notably, immunocompromised patients and  
22 their providers have preferred anti-spike neutralizing monoclonal antibodies due to the potential for  
23 drug-drug interactions and the overall positive outcomes from prior reports [6].

24 High-risk individuals were also offered telemedicine follow-up using the COVID-19 remote patient  
25 monitoring program. Using this program, we reviewed the clinical symptoms of patients at time of SARS-  
26 CoV-2 diagnosis until completion of NM/R therapy, at which point patients who met criteria for release  
27 of isolation graduated from the program. Electronic Health Records were reviewed to identify  
28 "rebound" of clinical symptoms following completion of 5-day course of NM/R therapy.

29 Rebound was defined as recurrence of COVID-19 symptoms following successful completion of 5 days of  
30 NM/R therapy and was assessed for up to 30 days after treatment. To meet criteria, patients needed to  
31 have demonstrated 1) test-confirmed diagnosis of symptomatic SARS-CoV-2 infection prior to initiation  
32 of NM/R, 2) improvement in most or all symptoms during therapy with NM/R, and 3) absence of an  
33 alternate explanation for recurrent symptoms. Patients who failed to complete the 5-day course of  
34 NM/R, lacked significant improvement in symptoms (deemed treatment failure), or had persistent  
35 symptoms signifying long COVID were excluded from analysis of the rebound phenomenon. Institutional  
36 diagnostic stewardship task force guidelines prevent repeat testing within 90 days following diagnosis of  
37 SARS-CoV-2 unless clearly indicated. Hence microbiologic data including viral load to demonstrate  
38 pattern of viral replication in the context of rebound was not available for all patients. Basic descriptive  
39 statistics of the patients meeting our inclusion criteria were performed using R version 4.1.2. [7].

## 40 RESULTS

41 The study population of 483 patients had a median age of 63 years (interquartile range [IQR] 51-74) and  
42 56% were female. The median Monoclonal Antibody Screening Score was 3 (IQR, 1-5), suggesting a high-  
43 risk for severe disease progression. The majority (n=448 (93%)) were fully vaccinated. Time from positive  
44 SARS-CoV-2 test to being prescribed NM/R was 1 day (IQR, 1-2) (Table 1). Within 30 days of diagnosis, 2  
45 (0.4%) patients were hospitalized for reasons unrelated to rebound, and both required intensive care  
46 unit (ICU) level of care. No patients died (Table 1).

47 Four patients (0.8%) experienced rebound of symptoms at a median of 9 days (IQR, 7-14.5) after NM/R  
48 treatment. All four patients were fully vaccinated. Two patients presented to their primary care

1 provider. No patient needed hospitalization. All improved without requiring further COVID-19 directed  
2 therapies. No alternative diagnoses were found. Their clinical course and outcome are detailed below.

3 **Patient 1:**

4 75-year-old male with coronary artery disease, chronic obstructive pulmonary disease, diabetes mellitus  
5 started NM/R 3 days after testing positive for SARS-CoV-2 by nasopharyngeal PCR. He was fully  
6 vaccinated (3-doses of mRNA vaccine; last dose administered 156 days prior). His symptoms of cough,  
7 rhinorrhea, headache, and fever resolved by day 5 post NM/R. However, nineteen days after NM/R, he  
8 had increased cough with wheezing and dyspnea. CT chest demonstrated mild ground-glass and  
9 reticular opacities consistent with COVID-19 pneumonia. He received symptom-directed therapy.

10 **Patient 2:**

11 40-year-old female with obesity, chronic kidney disease, and hypertension started on NM/R 3 days after  
12 testing positive for SARS-CoV-2 by home nasal antigen test. She was fully vaccinated (3 doses of mRNA  
13 vaccine; last dose administered 119 days prior). Her symptoms of fever, non-productive cough,  
14 palpitations, and diarrhea resolved at completion of NM/R regimen. Six days later, she had worsening  
15 pharyngitis, fatigue, malaise managed with symptom-directed therapy.

16 **Patient 3:**

17 69-year-old male with hypertension and obesity started NM/R 1 day after testing positive for SARS-CoV-  
18 2 by nasopharyngeal PCR. He was fully vaccinated (3 doses of mRNA vaccine; last dose administered 185  
19 days prior). His symptoms of fever, cough, rhinorrhea, myalgia, and dyspnea had improved following  
20 completion of NM/R therapy. Ten days later, he had worsening rhinorrhea and cough, which was  
21 managed with symptom-directed therapy.

22 **Patient 4:**

23 70-year-old male with history of prostate cancer, hypertension, dyslipidemia, obesity started NM/R 1-  
24 day after testing positive for SARS-CoV-2 by home nasal antigen test. He was fully vaccinated (3 doses of  
25 mRNA vaccine; last dose administered 171 days prior). His symptoms of productive cough, fever,  
26 rhinorrhea, headache, and pharyngitis had resolved at completion of NM/R regimen. Eight days later, he  
27 had recurrence of rhinorrhea and sinus congestion which was managed with symptom-directed therapy.

28 **DISCUSSION**

29 Anecdotal reports of rebound phenomenon after completion of NM/R is being increasingly reported [3].  
30 Our retrospective review of 483 patients with mild SARS-CoV-2 infection treated with NM/R found a low  
31 rate of rebound phenomenon. Only 0.8% of patients experienced recurrence of symptoms following  
32 completion of therapy. Overall, high-risk patients who received early NM/R treatment had favorable  
33 outcomes with 0.4% requiring hospitalization and ICU admission, and no deaths at 30 days after  
34 diagnosis.

35 One explanation for this rebound phenomenon is the resumption of SARS-CoV-2 viral replication  
36 following completion of therapy, triggering a secondary immune-mediated response that manifests as  
37 recurrence of clinical symptoms. The manufacturer had reported to the FDA of several such cases of  
38 rebound in SARS-CoV-2 RNA levels in <2% of patients at day 10 or 14 following NM/R completion [1]. It  
39 is unclear if this represents resumption of viral replication in persons with incompletely controlled  
40 infection due to inadequate length of therapy (5-days) or a natural biphasic pattern of viral replication  
41 [8]. Data about potential presence of viral rebound in patients from EPIC-HR who received placebo  
42 therapy would be helpful in delineating this question. Furthermore, prospective studies evaluating viral  
43 RNA replication during and following completion of NM/R in those with and without relapse symptoms  
44 are needed. Because institutional guidance did not allow for repeat testing, we were not able to  
45 determine viral replication kinetics in this retrospective review.

46 Extending the duration of NM/R treatment to prevent this rebound phenomenon has been suggested.  
47 However, our data suggests that this may not be necessary. The rate of rebound is low (0.8%) and  
48 extending treatment to all patients to prevent rebound in the small number of patients would be a

1 suboptimal strategy. Identifying risk factors may help distinguish patients who are more likely to  
2 experience rebound phenomenon. We are unable to define risk factors in this study due to small  
3 number of cases, but it is notable that the four patients with rebound had multiple underlying medical  
4 comorbidities and had received SARS-CoV-2 vaccine more than 90 days prior to NM/R therapy. Studies  
5 have shown that persons with multiple comorbidities are more likely to have unfavorable course despite  
6 COVID-19 directed therapies. Nonetheless, the four patients with rebound had favorable outcomes even  
7 without additional COVID-19-directed treatment.

8 A limitation of our review was the retrospective nature of the chart review and the challenges of  
9 subjective evaluation of symptom rebound. To mitigate the risk of ascertainment bias, all patients  
10 receiving NM/R had close clinical follow-up and opportunity to self-report progression of symptoms  
11 through a centralized COVID-19 remote monitoring program until completion of therapy and graduation  
12 from the program. We also employed 2-independent physician adjudication to identify suspected cases  
13 of rebound. The results of this study should be interpreted in the context of our patient cohort, who  
14 have high vaccination rates but with an under-representation of immunocompromised individuals. As  
15 noted above, in our program, immunocompromised patients and their providers preferred anti-spike  
16 neutralizing monoclonal antibody therapy or intravenous remdesivir, instead of NM/R, for the treatment  
17 of COVID-19.

#### 18 **CONCLUSION**

19 Rebound after NM/R treatment is uncommon in our population of high-risk, but mostly non-  
20 immunocompromised patient population. Among the patients who developed rebound of symptoms  
21 after NM/R treatment, the clinical presentation was mild and did not require COVID-19 directed  
22 therapies. In our cohort, the outcomes of patient with rebound phenomenon were very good overall.

23  
24 Notes:

25 Funding:

26 None

27  
28 Potential conflicts:

29 Raymund Razonable MD declares grants/contracts with Roche, Regeneron and Gilead and nference;  
30 consulting fees from Merck, Glaxo Smith Kline; and is on data safety monitoring/advisory board for  
31 Novartis

32 John C. O'Horo reports grants paid to institution and unrelated to this work from MITRE Corporation and  
33 nference, Inc; personal consulting fees from Bates College; a leadership or fiduciary role on the COVID-  
34 19 Treatment Guideline Panel and UTI Treatment Guideline Panel for the Infectious Disease Society of  
35 America.

36 Other authors declare no relevant conflicts of interest

1 **REFERENCES**

- 2 1. *FDA Paxlovid Emergency Use Authorization.*  
3 2021(<https://www.fda.gov/media/155050/download>).
- 4 2. Hammond, J., et al., *Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.* N Engl  
5 J Med, 2022. **386**(15): p. 1397-1408.
- 6 3. Kalpana Gupta, J.S., Gary Stack, Michael Charness, *Rapid Relapse of Symptomatic SARS-CoV-2*  
7 *Infection Following Early Suppression with Nirmatrelvir/Ritonavir.* Research Square, April 26,  
8 2022. **Pre Print.**
- 9 4. Razonable, R.R., et al., *A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies*  
10 *to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model.*  
11 Mayo Clin Proc, 2021. **96**(5): p. 1250-1261.
- 12 5. Razonable, R.R., R. Ganesh, and D.M. Bierle, *Clinical Prioritization of Antispike Monoclonal*  
13 *Antibody Treatment of Mild to Moderate COVID-19.* Mayo Clin Proc, 2022. **97**(1): p. 26-30.
- 14 6. Yetmar, Z.A., et al., *Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant*  
15 *Recipients.* Open Forum Infect Dis, 2021. **8**(6): p. ofab255.
- 16 7. *R Core Team (2021). R: A language and environment for statistical computing. R Foundation for*  
17 *Statistical Computing, Vienna, Austria. 2021.*
- 18 8. Neant, N., et al., *Modeling SARS-CoV-2 viral kinetics and association with mortality in*  
19 *hospitalized patients from the French COVID cohort.* Proc Natl Acad Sci U S A, 2021. **118**(8).

1 **Table 1: Baseline demographics of patients with mild-to-moderate SARS-CoV-2 infection**  
 2 **treated with NM/R**

Characteristic	Patients treated with NM/R (n=483)
<b>Ethnicity</b>	
Hispanic/Latino	5 (1%)
Not Hispanic/Latino	461 (95%)
Other/Did not disclose	17 (4%)
<b>Sex</b>	
Male	211 (44%)
Female	272 (56%)
Age (years)	63 (IQR 51-74)
BMI	28 (IQR 26-31)
Monoclonal Antibody Screening Score (MASS)	3 (IQR 1-5)
Fully Vaccinated	448 (93%)
<b>Days from positive test to prescription</b>	1 (IQR 1-2)
<b>Outcomes</b>	
Hospital Admission within 30 days	2 (0.4%)
ICU Admission within 30 days	2 (0.4%)
Death within 30 days	0 (0%)

3  
4